X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EYP-1901 delivers vorolanib, a selective tyrosine kinase inhibitor formulated in a solid bioerodible insert using EyePoint’s proprietary sustained-release Durasert E™ technology. It is under phase 2 clinical development for the treatment of diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $201.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
EYP-1901 (vorolanib) is being developed as a sustained delivery treatment for wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Yutiq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alimera Sciences
Deal Size: $82.5 million Upfront Cash: $75.0 million
Deal Type: Divestment May 18, 2023
Details:
EYP-1901 (vorolanib) is being developed as an investigational sustained delivery, for maintenance treatment of wet AMD combining a bioerodible formulation of Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. RLYB114 is a C5-targeted Affibody® molecule conjugated to polyethylene glycol (PEG).
Lead Product(s): RLYB114
Therapeutic Area: Ophthalmology Product Name: RLYB114
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Rallybio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2023
Details:
Positive safety and efficacy data from the DAVIO Phase 1 clinical trial of EYP-1901, a Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor showed no reports of ocular or drug-related systemic serious adverse events.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
EYP-1901 (vorolanib) is being developed as an investigational sustained delivery treatment combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
